STEVEN KING - 31 Mar 2021 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Role
Director
Signature
/s/ Steven W. King
Issuer symbol
OTLC
Transactions as of
31 Mar 2021
Net transactions value
$0
Form type
4
Filing time
16 Jul 2021, 17:37:41 UTC
Next filing
08 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OTLC Common Stock Conversion of derivative security +3,291,720 +8456% 3,330,647 31 Mar 2021 By Artius Bioconsulting F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLC Series A Convertible Preferred Stock Conversion of derivative security -3,292 -100% 0 31 Mar 2021 Common Stock 3,291,720 By Artius Bioconsulting F1, F3
transaction OTLC Stock Options Award $0 +357,412 $0.000000 357,412 08 Jul 2021 Common Stock 357,412 $0.1626 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.
F2 Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vests immediately on the date of grant.
F3 Shares of the Series A Convertible Preferred Stock does not expire.